NasdaqGS:BMRNBiotechs
BioMarin Pharmaceutical (BMRN): Margin Surge Reinforces Bullish Narratives Despite Revenue Lag
BioMarin Pharmaceutical (BMRN) delivered a net profit margin of 16.8%, up from 11.7% a year ago, with earnings soaring 61.5% over the past twelve months compared to a five-year average annual decline of 8.5%. While revenue is forecast to climb at 6.5% per year, lagging the broader US market’s 10.1% estimate, earnings are expected to accelerate at a 21.3% annual rate, outpacing the market’s 15.6%. The balance of strong profit growth and improved margins, together with a share price of $53.49...